insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

RPRX · Royalty Pharma PLC - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · RPRX

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue$2.38B$2.26B$2.35B$2.24B$2.29B$2.12B
Cost of Revenue------
Gross Profit------
R&D$452.00M$2.00M$52.00M$177.11M$200.08M$26.29M
SG&A$573.48M$236.67M$249.75M$227.30M$182.83M$181.72M
Total Operating Expenses$818.67M$971.13M$862.40M$1.93B$858.75M$526.95M
D&A$0-----
Operating Income$1.56B$1.29B$1.49B$307.06M$1.43B$1.60B
Interest Expense$307.66M$225.51M$187.19M$187.96M$166.14M$157.06M
Income Tax$0$0$0$0$0$0
Net Income$770.95M$858.98M$1.13B$42.83M$619.73M$975.04M
EPS - Basic$1.79$1.92$2.54$0.10$1.49$1.32
EPS - Diluted$1.78$1.91$2.53$0.10$1.49$1.32

Balance Sheet

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash & Equivalents$618.70M$929.03M$477.01M$1.71B$1.54B$1.01B
Accounts Receivable------
Inventory------
Accounts Payable------
Current Assets$1.53B$1.80B$1.27B$2.55B$2.88B$2.70B
Total Assets$19.62B$18.22B$16.38B$16.81B$17.52B$16.02B
Current Liabilities$636.21M$1.25B$161.38M$1.17B$171.25M$307.89M
Long-term Debt$8.57B$6.61B$6.14B$6.12B$7.10B$5.82B
Total Liabilities$9.91B$7.88B$6.30B$7.29B$7.27B$6.12B
Stockholders' Equity$9.71B$10.34B$10.08B$9.53B$10.25B$9.90B
Retained Earnings$2.36B$2.85B$2.52B$1.96B$2.26B$1.92B

Cash Flow

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Cash Flow$2.49B$2.77B$2.99B$2.14B$2.02B$2.03B
Investing Cash Flow($1.61B)($2.68B)($2.07B)($1.03B)($1.87B)($2.76B)
Financing Cash Flow($1.19B)$361.14M($2.15B)($944.86M)$385.11M$1.49B
CapEx------
Free Cash Flow------

Ratios

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Profitability
Gross margin------
Operating margin65.6%57.1%63.4%13.7%62.5%75.2%
EBITDA margin65.6%-----
Net margin32.4%37.9%48.2%1.9%27.1%45.9%
Free cash flow margin------
FCF / Net income------
R&D / Revenue19.0%0.1%2.2%7.9%8.7%1.2%
SG&A / Revenue24.1%10.5%10.6%10.2%8.0%8.6%
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%
Return on assets3.9%4.7%6.9%0.3%3.5%6.1%
Return on equity7.9%8.3%11.3%0.4%6.0%9.9%
Return on invested capital8.5%7.6%9.2%2.0%8.2%10.2%
Liquidity
Current ratio2.401.447.902.1916.818.76
Quick ratio2.401.447.902.1916.818.76
Cash ratio0.970.742.961.479.003.28
Leverage
Debt / Equity0.880.640.610.640.690.59
Debt / Assets0.440.360.370.360.410.36
Debt / EBITDA5.50-----
Interest coverage5.1x5.7x8.0x1.6x8.6x10.2x
Equity multiplier2.021.761.621.771.711.62
Liabilities / Assets0.500.430.380.430.410.38
Efficiency
Asset turnover0.120.120.140.130.130.13
Inventory turnover------
Days sales outstanding------
Days inventory outstanding------
Days payable outstanding------
Cash conversion cycle------
Valuation
P / E21.7x13.4x11.1x395.2x26.7x37.9x
P / B2.2x1.5x1.7x1.8x1.6x1.9x
P / S9.2x6.7x7.2x7.7x7.2x8.9x
EV / EBITDA19.1x-----
Growth
Revenue growth (YoY)5.1%-3.9%5.2%-2.3%7.9%-
Revenue CAGR (3y)2.1%-0.4%3.5%---
Revenue CAGR (5y)2.3%-----
Gross profit growth (YoY)------
Operating income growth (YoY)20.7%-13.4%385.9%-78.5%-10.3%-
Net income growth (YoY)-10.2%-24.3%2549.5%-93.1%-36.4%-
EPS growth (YoY)-6.8%-24.5%2430.0%-93.3%12.9%-
EPS CAGR (3y)161.1%8.6%24.2%---
EPS CAGR (5y)6.2%-----
FCF growth (YoY)------
FCF CAGR (5y)------
Book value growth (YoY)-6.1%2.6%5.9%-7.1%3.6%-

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Product / service

$2.38B total
Financial Royalty Assets$2.26B · 95.1%
Royalty Income Other$117.04M · 4.9%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

0.91
Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

5/9
Neutral
  • ✓Net income positive
  • ✓Operating cash flow positive
  • ✗ROA improved YoY
  • ✓Cash flow > net income
  • ✗Long-term debt decreased
  • ✓Current ratio improved
  • ✓No share dilution
  • -Gross margin improved
  • ✗Asset turnover improved

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Royalty Pharma plc against the 5 most active filers in the same SIC group.

Dividends

$0.91/share trailing 12 months · +5.8% YoY

Ex-datePer share
May 15, 2026$0.2350
Feb 20, 2026$0.2350
Nov 14, 2025$0.2200
Aug 15, 2025$0.2200
May 16, 2025$0.2200
Feb 21, 2025$0.2200
Nov 15, 2024$0.2100
Aug 16, 2024$0.2100
May 16, 2024$0.2100
Feb 15, 2024$0.2100
Nov 16, 2023$0.2000
Aug 17, 2023$0.2000
May 18, 2023$0.2000
Feb 15, 2023$0.2000
Nov 17, 2022$0.1900
Aug 18, 2022$0.1900
May 19, 2022$0.1900
Feb 17, 2022$0.1900
Nov 18, 2021$0.1700
Aug 19, 2021$0.1700
May 19, 2021$0.1700
Feb 18, 2021$0.1700
Nov 19, 2020$0.1500
Sep 14, 2020$0.1500